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Objectives. We compared postoperative analgesic requirements between women with early stage endometrial cancer treated by
total abdominal hysterectomy (TAH) or total laparoscopic hysterectomy (TLH). Methods. 760 patients with apparent stage I
endometrial cancer were treated in the international, multicentre, prospective randomised trial (LACE) by TAH (𝑛 = 353) or
TLH (𝑛 = 407) (2005–2010). Epidural, opioid, and nonopioid analgesic requirements were collected until ten months after surgery.
Results. Baseline demographics and analgesic use were comparable between treatment arms. TAH patients were more likely to
receive epidural analgesia than TLH patients (33% versus 0.5%, 𝑃 < 0.001) during the early postoperative phase. Although opioid
use was comparable in the TAH versus TLH groups during postoperative 0–2 days (99.7% versus 98.5%, 𝑃 = 0.09), a significantly
higher proportion of TAHpatients required opioids 3–5 days (70%versus 22%,𝑃 < 0.0001), 6–14 days (35%versus 15%,𝑃 < 0.0001),
and 15–60 days (15% versus 9%, 𝑃 = 0.02) after surgery. Mean pain scores were significantly higher in the TAH versus TLH group
one (2.48 versus 1.62, 𝑃 < 0.0001) and four weeks (0.89 versus 0.63, 𝑃 = 0.01) following surgery. Conclusion. Treatment of early
stage endometrial cancer with TLH is associated with less frequent use of epidural, lower post-operative opioid requirements, and
better pain scores than TAH.
1. Introduction
Endometrial cancer is the most common gynaecological
cancer in developed countries and the current standard
of treatment is hysterectomy and bilateral salpingectomy
using an open abdominal surgical approach [1]. Three recent
clinical trials have shown that a laparoscopic approach to
surgery results in shorter hospital stay and fewer adverse
events compared with open surgery [2–5] and two of these
trials found better quality of life outcomes [3, 5]. Epidural
and nonepidural opioid analgesia may be used for pain
management following both, open or laparoscopic surgery,
and guidelines are available for anaesthetic prescription and
monitoring [6]. Although epidural analgesia may decrease
the risk of cardiovascular and pulmonary complications in
high-risk patients undergoing major surgery, it is invasive,
costly, time consuming, and labour intensive [7]. There is
developing evidence that other forms of regional analgesia
may be more cost effective without sacrificing efficacy [7,
8].
Minimally invasive procedures have been found to be
associated with smaller postoperative analgesia requirements
compared with open surgery in patients treated for gynae-
cological cancers [9–12] and in ovarian metastasectomy
from gastric cancer [13]. There is also evidence that total
laparoscopic hysterectomy (TLH) offers benefits over vaginal
hysterectomy in terms of reduced opioid and NSAID anal-
gesic requirements following surgery [14].
2 Minimally Invasive Surgery
Minimally invasive procedures for endometrial cancer,
including total laparoscopic, laparoscopic-assisted vaginal,
or robotic-assisted laparoscopic hysterectomy, are associ-
ated with significantly reduced postoperative analgesic use
compared with open abdominal laparotomic hysterectomy
[5, 15–18]; however, these studies only followed patients’
perioperative analgesic requirements and there is a lack of
randomised clinical trials comparing postoperative analgesic
use between open and minimally invasive treatment arms
during a more extended period of time after surgery and a
lack of data from the Australian context.
This report examines differences in postoperative opioid
and analgesic prescription between patients with apparent
stage I endometrial cancer undergoing TLH or total abdom-
inal hysterectomy (TAH) and outcomes of these patients up
to ten months after surgery.
2. Methods
The LACE trial (laparoscopic approach to cancer of the
endometrium) commenced recruitment in October 2005,
and a total of 760 women with apparent stage I endometrial
cancer were enrolled by June 2010 through one of 20 partici-
pating tertiary gynaecological oncology centres in Australia,
New Zealand, Switzerland, and Hong Kong. The trial design
and methodology, as well as QOL and AE outcomes, have
been previously described [3, 4]. Women were eligible if they
were 18 years or older and had a histologically confirmed
endometrioid adenocarcinoma of the endometrium of any
grade, an Eastern Cooperative Oncology Group (ECOG)
score of less than two, and imaging studies (computed tomog-
raphy (CT) of the abdomen and pelvis and chest radiograph
or chest CT) suggesting the absence of extrauterine disease.
Patients were excluded if they had histological cell type
other than endometrioid on curettage, clinically advanced
disease (stage II–IV) or bulky lymph nodes on imaging,
uterine size greater than 10 weeks of gestation, estimated life
expectancy of less than 6months, medically unfit for surgery,
or patient compliance or geographic proximity preventing
adequate followup or if they are unfit to complete quality of
life questionnaires. FIGO 2009 staging criteria were used.
Overall, 407 patients were randomised to TLH and 353
to TAH using block randomisation stratified by centre and
grade of differentiation. Surgeons involved in the trial were
all accredited gynaecological oncologists who had completed
at least 20 TLHs, submitted video footage of a TLH, and
performed a TLH live in the presence of a senior accredited
surgeon. Seven patients withdrew before completing six
weeks followup and were included in baseline and periop-
erative analyses but excluded from long-term comparison of
analgesic use.
Details of medication use including medication name,
dose, frequency, unit, route of administration, start date, and
end date of prescription were recorded for each patient by
the trial nurses at each hospital. Information was collected
in detail during the perioperative period and then during
the patients’ postoperative one-week, four-weeks, three-
month and six-month data clinical followup. Recorded start
dates and end dates of analgesic prescription were used
to categorise analgesic use into more distinct periods of
time, up to a maximum record of 310 days (ten months)
postoperatively.
Free-text entries of all medication names were scanned
and classified into drug classes by one medical professional.
All drugs classified as analgesics were further categorised
by one of the authors (J. Baker) in consultation with
anaesthetists, into opioid and nonopioid analgesia, and opi-
oid analgesics further classified by route of administration
(epidural, parenteral, or oral).
2.1. Statistical Analysis. Intention-to-treat analysis was used.
Baseline demographic and clinical characteristics were com-
pared between treatment arms using descriptive statistics.
Descriptive statistics and chi-squared tests of heterogeneity
were used to compare epidural, parenteral, or oral opioid
requirements within two days of surgery and postoperative
opioid andnonopioid analgesic requirements up to 10months
following surgery between treatment arms, based on compar-
isons of prescription start and end dates to date of surgery.
Perioperative opioid use within two days of surgery was
categorized by the most invasive route of administration for
each patient. Long-term use of analgesics was explored by
counting each patient in more than one analgesic category if
they were prescribed more than one type of analgesic class. 𝑡-
tests were used to compare postoperative pain scores between
treatment arms.
3. Results
Within the TAH group (𝑁 = 353), 247 patients underwent
a vertical midline incision, and 99 had a low abdominal
transverse incisions. Among the TLH group, 24 patients
needed to be converted and 11 of these underwent a vertical
midline incision. Five patients randomised to TAH requested
and received a TLH procedure (overall conversion rate 3.8%).
Baseline characteristics and analgesic use were comparable
between treatment arms, with 67% of patients overall not
taking any analgesia, 29% taking nonopioid, and 3% taking
opioid analgesia (Table 1).
Overall, 121/353 (34%) TAH and 2/407 (0.5%) TLH
patients received pain relief through an epidural during the
study period (𝑃 < 0.0001). At data collection two days
after surgery, significantly more patients with TAH (116/353;
33%) had received an epidural compared with 2/407 (0.5%)
of TLH patients (𝑃 < 0.0001, Table 2). Mean pain scores were
significantly higher in theTAHversusTLHgroup at oneweek
(2.48 versus 1.62, 𝑃 < 0.0001), four weeks (0.89 versus 0.63,
𝑃 = 0.01), and six months (0.45 versus 0.27, 𝑃 = 0.04), but
not at three months following surgery (Table 2).
During the first two postoperative days, although a
similar proportion of patients in the TAH or TLH groups
were prescribed opioid analgesia (99.7% versus 98.5%, 𝑃 =
0.09) and NSAIDS (61% versus 60%, 𝑃 = 0.7), a significantly
higher proportion of TAH patients required Paracetamol
(98% versus 95%, 𝑃 = 0.03). At 3–5 days after surgery,
significantly higher proportions of patients allocated to TAH
required opioid analgesia (70% versus 22%, 𝑃 < 0.0001),
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Table 1
TLH
(𝑁 = 407)
TAH
(𝑁 = 353)
Age in years, mean (SD) 63 (10) 63 (11)
BMI category† 𝑛 (%) 𝑛 (%)
Normal (18.50–24.99) 47 (12) 46 (14)
Overweight (25.00–29.99) 98 (25) 72 (21)
Obesity class I (30.00–34.99) 77 (20) 87 (26)
Obesity class II (35.00–39.99) 81 (21) 61 (18)
Obesity class III (≥40) 86 (22) 74 (22)
Education
Completed ≤12 years of school 270 (70) 232 (70)
Completed >12 years of school 118 (30) 99 (30)
Employment
Retired 170 (44) 134 (40)
Employed full time 55 (14) 42 (13)
Employed part time or casual 44 (11) 54 (16)
Other 119 (31) 101 (31)
Marital status
Married or living together 243 (63) 212 (64)
Other 145 (37) 119 (36)
Private health insurance
Yes 101 (26) 90 (27)
No 287 (74) 241 (73)
Income
Less than AUS$40,000 261 (67) 207 (62)
AUS$40,000+ 83 (21) 82 (25)
Not answered 44 (11) 42 (13)
Birth country
Australia 249 (64) 219 (66)
Other 139 (36) 112 (34)
ECOG performance status
0 352 (86) 303 (86)
1 55 (14) 50 (14)
Baseline analgesic use
(pts categorised by strongest class
taken)
No analgesia 273 (67) 239 (68)
Nonopioid analgesia 120 (29) 103 (29)
Opioid analgesia 14 (3) 11 (3)
Data are number of patients (%). TLH: total laparoscopic hysterectomy.
TAH: total abdominal hysterectomy. BMI: body mass index. ECOG: Eastern
CooperativeOncologyGroup. Numbers do not always add up to 760 because
of missing demographic data. †Based on WHO categories.
NSAIDs (38%versus 21%,𝑃 < 0.0001), andParacetamol (91%
versus 62%, 𝑃 < 0.0001). This effect persisted at 6–14 days
after surgery, with significantly higher proportions of patients
allocated to TAH still requiring opioid analgesia (35% versus
15%, 𝑃 < 0.0001), NSAIDs (24% versus 15%, 𝑃 = 0.003), and
Paracetamol (65% versus 46%, 𝑃 < 0.0001). At 15–60 days
after surgery, a significantly higher proportion in the TAH
Table 2: Opioid use ≤2 days after surgery.
TLH (𝑁 = 407) TAH (𝑁 = 353)
𝑃 value
𝑛 (%) 𝑛 (%)
Route of postoperative
opioid use∗
Epidural 2 (0.5) 116 (33)
Parenteral 392 (96) 230 (65)
Oral 5 (1) 2 (0.6)
Nil 8 (2) 5 (1)
Mean (SD) Mean (SD)
Painscore
Week 1 1.62 (2.01) 2.48 (2.13) <0.0001
Week 4 0.63 (1.34) 0.89 (1.5) 0.01
Month 3 0.48 (1.39) 0.54 (1.26) 0.59
Month 6 0.27 (0.98) 0.45 (1.27) 0.04
∗Patients categorised by the most invasive route of administration.
group still required opioid analgesia (15% versus 9%, 𝑃 =
0.02) and Paracetamol (40% versus 28%, 𝑃 = 0.0004), but a
similar proportion in both treatment arms required NSAIDs
(13% versus 9%, 𝑃 = 0.2). Analgesic use was comparable
between groups after 60 days after surgery (Table 3).
4. Discussion
Althoughpatients undergoingTAHorTLHrequirednarcotic
analgesia for the first two days after surgery, those undergoing
TLH recovered faster and fewer required analgesia by day
three after surgery. This difference in analgesic requirements
between the treatment groups persisted until after two
months following surgery. Both the surgical approach and the
epidural procedure could have contributed to these findings,
as well as the greater prevalence of adverse surgical events
observed among the TAH group [4]. Despite advances in the
aftercare for patients with TAH, such as through fast-track
surgical care [19], a significantly greater number of women
require epidural analgesia for open abdominal compared
to laparoscopic surgery for stage I endometrial cancer. As
the LACE trial was unblinded, the anaesthetic prescription
choices of the anaesthetists can be influenced by the planned
procedure. As TAH patients require hospital care for a sig-
nificantly longer time than TLH patients [4, 5, 20] providing
an epidural conforms with recommendations to lessen the
risk of prolonged immobilisation and the subsequent risk
of thromboembolism in oncology patients [6, 21]. On the
other hand, there is little evidence of decreased perioperative
morbidity or mortality with epidural analgesia, particularly
in the low to medium risk surgical population [7].
Our study is in agreement with a smaller Phase III
trial conducted in the Netherlands which compared clinical
and postoperative outcomes in 283 patients treated within
21 hospitals who were assigned to either laparoscopic or
the standard procedure of open surgery for early stage
endometrial cancer. Similar to the present study, this trial
found the duration of pain after surgery to be significantly
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Table 3: Postoperative analgesic use, excluding 7 pts without 6-week
followup∗.
TLH (𝑁 = 404) TAH (𝑁 = 349)
𝑃 value
𝑛 (%) 𝑛 (%)
Analgesic classes 0–2
days after surgery
Opioid 398 (98.5) 348 (99.7) 0.09
NSAID 242 (60) 214 (61) 0.69
Paracetamol 384 (95) 342 (98) 0.03
No analgesia — —
Analgesic classes 3–5
days after surgery
Opioid 87 (22) 246 (70) <0.0001
NSAID 86 (21) 132 (38) <0.0001
Paracetamol 252 (62) 317 (91) <0.0001
No analgesia 125 (31) 14 (4)
Analgesic classes 6–14
days after surgery
Opioid 60 (15) 121 (35) <0.0001
NSAID 61 (15) 82 (24) 0.0034
Paracetamol 187 (46) 227 (65) <0.0001
No analgesia 190 (47) 86 (25)
Analgesic classes 15–60
days after surgery
Opioid 37 (9) 52 (15) 0.015
NSAID 37 (9) 44 (13) 0.24
Paracetamol 112 (28) 139 (40) 0.0004
No analgesia 271 (67) 180 (52)
Analgesic classes 61–150
days after surgery
Opioid 23 (6) 20 (6) 0.98
NSAID 20 (5) 20 (6) 0.63
Paracetamol 42 (10) 48 (14) 0.16
No analgesia 342 (85) 282 (81)
Analgesic classes 151–310
days after surgery
Opioid 13 (3) 10 (3) 0.78
NSAID 12 (3) 11 (3) 0.89
Paracetamol 19 (5) 16 (5) 0.94
No analgesia 369 (91) 319 (91)
NSAID: nonsteroidal anti-inflammatory drugs.
∗Patients counted more than once if taking more than one analgesic class.
shorter for TLH versus TAH patients (median 3 (0–7) versus
5 days (0–7), 𝑃 < 0.0001) [22]. However, this smaller
trial followed analgesic outcomes perioperatively only, did
not compare epidural use between treatment arms, did not
distinguish between different classes of analgesia, and did not
use or report pain score outcomes.
Our study findings are also similar to those of a prospec-
tive cohort study which found that women undergoing
either laparoscopic or robotic surgery for endometrial cancer
reported little need for opioid analgesia (45% did not require
any analgesia, 34% required nonopioid analgesia, and only
21% required opioid analgesia) at 3-4weeks after surgery [23].
In our study, during the comparable time period of 15–60
days after surgery, few patients undergoing TLH surgery had
requirement for opioids (67% did not require analgesia, 28%
required Paracetamol, 9% requiredNSAIDs, and 9% required
opioid analgesia). Our study also supports findings from
a prospective cohort study comparing minimally invasive
surgery to open surgery [15]. This study involved 182 con-
secutive patients undergoing surgery for early endometrial
cancer or endometrial hyperplasia with atypia and found
that the patients receiving laparoscopically assisted vaginal
hysterectomy (LAVH) (𝑁 = 74) had less need for analgesia
than those receiving TAH (𝑁 = 108). Postoperatively, the
laparotomy surgery group also had more frequent prolonged
use of epidural analgesia than the LAVH group (72% versus
49%, 𝑃 < 0.01).
A retrospective analysis compared 181 consecutive
patients with endometrial cancer undergoing open (𝑁 = 97)
or minimally invasive staging hysterectomy (𝑁 = 84)
including LAVH, TLH, or robotic-assisted laparoscopic
hysterectomy using the da Vinci Surgical System, with or
without lymphadenectomy [16]. This study found that in
the open group, median surgery time was shorter (197
versus 288 minutes, 𝑃 < 0.0001). Median narcotic (13 versus
43mg morphine equivalents; 𝑃 < 0.0001) and antiemetic
(43% versus 25%; 𝑃 = 0.01) needs, however, were lower
for minimally invasive surgery already in the first 24 hours
postoperatively.
A systematic review summarised the safety and efficacy
of TLH versus open surgery in women with endometrial
cancer and included 4 randomised clinical trials. This review
specifically highlighted the reduced need for analgesia among
women as one of the benefits of laparoscopic surgery [14, 17].
Besides the specific evidence related to endometrial
cancer surgery to which the present study adds, there is also
evidence that analgesic requirements and pain are reduced
when minimally invasive surgery is applied to other gynae-
cological malignant conditions [11, 12] and are also less for
womenundergoing laparoscopic surgery for benign gynaeco-
logical conditions compared with an open surgical approach
[10, 20]. For example, a review article examining surgical
treatment for obese women with endometrial, cervical, and
ovarian cancer found evidence that laparoscopic surgery was
associated with less postoperative pain compared with open
surgery [9].
Strengths of the present study include the fact that
analgesic prescription can be compared between treatment
arms within the context of a randomised clinical trial, a
long follow-up period, distinction between different analgesic
classes, inclusion of pain score comparisons, and the fact that
a lower conversion rate than previous trials allows clearer
inferences to be made regarding treatment arms. Limitations
include the fact that the trial was unblinded, biasing decision-
making for epidural and analgesic prescription.
In summary, the results of this study show that laparo-
scopic surgery for endometrial cancer is associated with less
need for epidural and postoperative analgesic prescription
compared with open surgery, saving on costs of analgesia and
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highlighting a further significant benefit to patients and the
healthcare system of laparoscopic treatment over traditional
open abdominal surgery.
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